Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:28 AM
Ignite Modification Date:
2025-12-25 @ 4:28 AM
NCT ID:
NCT00582920
Eligibility Criteria:
Inclusion Criteria:
* Patients receiving intravenous biphosphonate therapy (zoledronic acid 4 mg or renal dose equivalent) as part of their treatment regimen, who are diagnosed with metastatic breast cancer involving surrounding bone.
* Patients must have had prior treatment zoledronic acid (4 mg or adjusted dose for renal function) within 8 weeks.
* The patients clinical status as assessed by a treating physician must be deemed appropriate for continuing treatment with zoledronic acid
* The patient's clinical status, as assessed by a treating physician, must be deemed appropriate for an evaluation with a bone scan
* The patient's medical status as assessed by a treating physician must be medically appropriate to receive zoledronic acid within the study time frame and in association with the study bone scan
Exclusion Criteria:
* No evidence of bone metastases, or less than 3 osseous lesions felt to be consistent with bone metastases, on most recent bone scan performed for clinical indications prior to study entry.
* Patients with illnesses, or conditions that would prevent them from understanding the nature of the study and complying with the protocol requirements
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
110 Years
Study:
NCT00582920
Study Brief:
Protocol Section:
NCT00582920